Table 2.
Outcomes After Autologous and Allogeneic Hematopoietic Cell Transplantation: Multivariate Analysis
| Parameter | HR | 95% CI | P Value |
|---|---|---|---|
| Autologous HCT | |||
| Overall survival | |||
| RD Status (positive) | 1.82 | 0.28–11.73 | .53 |
| Age ≥60 years | 3.31 | 0.38–28.81 | .28 |
| Diagnosis to HCT >252 d | 3.27 | 0.43–24.81 | .25 |
| MIPI intermediate or high | 2.12 | 0.37–12.20 | .40 |
| Disease-free survival | |||
| RD Status (positive) | 5.60 | 1.30–24.04 | .02 |
| Age ≥60 years | 10.05 | 1.12–90.39 | .04 |
| Diagnosis to HCT >252 d | 3.51 | 0.86–14.34 | .08 |
| MIPI intermediate or high | 1.53 | 0.31–7.63 | .60 |
| Transplant-related mortality | |||
| RD Status (positive) | 1.29 | 0.19–8.76 | .79 |
| Age >60 years | 0 | – | <.01 |
| Diagnosis to HCT >252 d | 0 | – | <.01 |
| MIPI intermediate or high | 0.89 | 0.10–8.13 | .92 |
| Relapse | |||
| RD Status (negative) | 0 | – | <.01 |
| Age <60 years | 0.22 | 0.02–2.17 | .20 |
| Diagnosis to HCT >252 d | 0.86 | 0.20–3.77 | .84 |
| MIPI low | 0 | – | <.01 |
| Allogeneic HCT | |||
| Overall survival | |||
| Chemosensitivity | 1.76 | 0.32–9.68 | .52 |
| RIC | 0.79 | 0.18–3.45 | .75 |
| MIPI intermediate or high | 0.43 | 0.07–2.55 | .35 |
| Diagnosis to HCT >252 d | 0.79 | 0.16–3.80 | .77 |
| Disease-free survival | |||
| Chemosensitivity | 1.17 | 0.26–5.33 | .84 |
| RIC | 1.08 | 0.32–3.68 | .90 |
| MIPI intermediate or high | 0.53 | 0.12–2.27 | .39 |
| Diagnosis to HCT >252 d | 0.64 | 0.17–2.40 | .51 |
| Comorbidity ≥3 | 0.85 | 0.17–4.32 | .84 |
| Transplant-related mortality | |||
| RIC | 0.21 | 0.03–1.68 | .14 |
| MIPI intermediate or high | 1.81 | 0.31–10.45 | .04 |
| Diagnosis to HCT >252 d | 0.51 | 0.06–4.21 | .54 |
| Comorbidity ≥3 | 0.23 | 0.01–3.53 | .29 |
| Relapse | |||
| Chemosensitivity | 2.25 | 0.34–14.71 | .40 |
| MAC | 0 | – | <.01 |
| MIPI intermediate or high | 1.42 | 0.13–15.26 | .77 |
| Diagnosis to HCT >252 d | 2.88 | 0.28–29.18 | .37 |
| Comorbidity ≥3 | 1.44 | 0.13–16.50 | .77 |
Shown are factors considered in Cox-model multivariate analysis. The hazard ratios with 95% confidence intervals (CI) and significance probability for each factor considered are shown. The reference groups were chemorefractory disease, myeloablative conditioning, low MIPI score, diagnosis to HCT time < 252 d, and comorbidity index of 1–2.
Abbreviations: HCT = hematopoietic cell transplantation; HR = hazard ratio; MAC = myeloablative conditioning; MIPI = Mantle Cell Lymphoma International Prognostic Index; RD = residual disease; RIC = reduced-intensity conditioning.